18,800 Shares in Genmab A/S (NASDAQ:GMAB) Purchased by Pilgrim Partners Asia Pte Ltd

Pilgrim Partners Asia Pte Ltd acquired a new position in Genmab A/S (NASDAQ:GMAB) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 18,800 shares of the company’s stock, valued at approximately $392,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. EverSource Wealth Advisors LLC raised its stake in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Cromwell Holdings LLC boosted its stake in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Genmab A/S during the 4th quarter valued at about $93,000. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several analyst reports. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Truist Financial lowered their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Trading Down 4.4 %

Shares of NASDAQ GMAB opened at $18.39 on Friday. Genmab A/S has a 12-month low of $18.30 and a 12-month high of $30.41. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of 10.57, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. The firm has a 50 day moving average of $20.67 and a 200 day moving average of $21.64.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.